CMEK162x2114


Protocolnummer:
Gesloten

Ziekenhuizen:
RadboudUMC Nijmegen
Universitair Medisch Centrum Utrecht

Titel:
A phase 1b/11 , multicenter , open label study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma.

Behandeling:
Lee011 and MEK162

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: ECOG performance status of 0-2, phase 1b enrolled patients may have evaluable disease only; phase 2 enrolled patients must have a least one measurable lesion as defined by RECIST 1.1 criteria. Ex: symptomatic brain metastases, impaired cardiac function, receiving treatment that is metabolized through CYP2A4, treatment with agents that are known to cause QTc prologation, retinal disease.

Contactpersoon:

Alle trials